Facing a tough battle against liver cancer? The LEAP-012 trial offers a glimpse into a new approach, but the journey is far from over. This study explored a combination therapy for those with unresectable, non-metastatic hepatocellular carcinoma (HCC), a particularly aggressive form of liver cancer.
HCC remains a formidable foe, and while transarterial chemoembolization (TACE) has been a standard treatment, many patients experience disease progression within a year. The LEAP-012 trial aimed to improve outcomes by combining TACE with two powerful agents: pembrolizumab (KEYTRUDA®), an immunotherapy drug, and lenvatinib (LENVIMA®), which targets blood vessel growth. The hope was that this combination would work synergistically to enhance the body's immune response, disrupt tumor blood supply, and ultimately, improve patient outcomes.
How did the trial work?
The LEAP-012 study was a large, double-blind, randomized Phase 3 trial. This means that neither the patients nor the doctors knew who was receiving the experimental treatment. A total of 480 patients with unresectable, non-metastatic HCC, who had not previously received systemic therapy, were enrolled.
Patients were divided into two groups:
- Experimental Arm: Received pembrolizumab (administered intravenously every 6 weeks), lenvatinib (either 12 mg or 8 mg daily, depending on body weight), and TACE.
- Control Arm: Received a dual placebo and TACE.
TACE involved delivering chemotherapy and embolic agents directly into the liver via the hepatic artery, starting 2-4 weeks after the systemic therapy began.
What were the key findings?
The primary goals of the trial were to assess:
- Progression-Free Survival (PFS): How long patients lived without their cancer worsening, as determined by an independent review.
- Overall Survival (OS): How long patients lived, regardless of disease progression.
Secondary endpoints included the objective response rate (ORR), duration of response (DOR), disease control rate (DCR), and safety.
At an interim analysis, the combination of KEYTRUDA + LENVIMA + TACE showed a statistically significant improvement in PFS compared to TACE alone. These results, presented at ESMO 2024 and published in The Lancet, confirmed the synergistic effect of the combined therapies.
But here's where it gets controversial... Despite the promising PFS results, the combination therapy did not significantly improve overall survival (OS). After reviewing the data, Merck and Eisai decided to end the trial early because the likelihood of achieving the OS threshold in future analyses was low.
- PFS: The combination regimen showed a statistically significant improvement in PFS compared to TACE alone (p < 0.001).
- OS: The trial did not meet the predefined significance threshold for OS, leading to early termination.
- Safety: The observed side effects were consistent with the known profiles of pembrolizumab and lenvatinib; no new safety concerns were identified.
What does this mean for patients?
The LEAP-012 trial reinforces the idea that combining immunotherapy and VEGF blockade with TACE has potential. However, it also highlights the challenge of translating improved tumor control into longer survival in intermediate-stage HCC. While the PFS benefit was substantial, the lack of OS improvement suggests that earlier immune modulation may not substantially alter long-term outcomes in this specific disease stage.
And this is the part most people miss... The study underscores the need for careful patient selection, the use of biomarkers to guide treatment, and optimizing the sequence of systemic and locoregional therapies in managing liver cancer.
Regulatory Context
Here's a twist: Despite the global trial closure, in June 2025, China's National Medical Products Administration (NMPA) approved KEYTRUDA + LENVIMA + TACE for unresectable, non-metastatic HCC. This approval was based on the PFS benefit and its clinical relevance in the local patient population. The results of this trial do not affect existing approvals of the pembrolizumab–lenvatinib combination for other cancers.
Key Takeaways:
- LEAP-012 met its PFS endpoint but did not demonstrate a statistically significant OS benefit compared to TACE alone.
- The trial was discontinued early due to a low probability of achieving the OS threshold.
- The safety profile was consistent with prior experience with pembrolizumab and lenvatinib.
- The findings emphasize the gap between improved tumor control and extended survival in intermediate-stage HCC.
- The results highlight the need for rational combinations, biomarker-guided selection, and optimized treatment sequencing in liver cancer management.
What are your thoughts? Do you think the PFS benefit justifies the use of this combination therapy, even without an OS benefit? How might biomarker-guided selection improve outcomes in future trials? Share your opinions in the comments below!
